Observation of the effect of medroxyprogesterone acetate combined with chemotherapy in treatment of metastatic breast cancer
CAI Jun-dong
LIU Jing
Abstract：Objective To evaluate the efficiency toxicity of medroxyprogesterone acetate combined with chemotherapy ( docetaxel + carboplatin) therapy for metastatic breast cancer.Methods Sixty patients with metastatic breast cancer were randomly divided into MTC group ( n =30) and TC group ( n =30 ).MTC group applied MTC scheme,in particular:medroxyprogesterone acetate 0.5,po,bid,d1-21,docetaxel 75 mg/m2,d1,carboplatin AUC 5 (300-400 mg/m2 ),d2,Intravenous drip,21 days for a cycle; TC group applied TC scheme,in particular:docetaxel 75 mg/m2,dl,carboplatin AUC 5 (300-400 mg/m2 ),d2,intravenous drip,21 days for a cycle.Every patients were cured six cycle.Results MTC group:CR10 cases,PR16 cases,SD4 cases,PD0 case,the total effective rate was 86.7％ ; TC Group:CR7 cases,PR12 cases,SD9 cases,PD2 cases,total effective rate was 63.3％,a significant difference between the two groups(P ＜0.05) ; MTC group one year survival rate was 90.0％ (27/30),TC group one year survival rate was 66.7 ％ (20/30).There were significant differences between the two groups (P ＜ 0.05 ) ; MTC group Ⅲ,Ⅳ leukocytes reduce accounted for 13.3 ％,increased food intake accounted for 80.0％ (24/30),weight gain accounted for 86.7％ (26/30),KPS score increase accounted for 66.7％ (20/30),TC group Ⅲ,Ⅳ leukocytes reduce accounted for 36.7％,increased food intake accounted for 6.7％ (2/30),weight gain accounted for 16.7％ (5/30),KPS score increase accounted for 20％ (6/30).Conclusion Medroxyprogesterone acetate combined with chemotherapy( docetaxel + carboplatin) therapy for metastatic breast cancer to further improve efficiency and prolong survival,toxicity was significantly reduced.
Keywords：Metastatic breast cancerMedroxyprogesteroneChemotherapyDocetaxelCarboplatin
Publication Date：2012-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)